NuCana to Present at the Jefferies Global Healthcare Conference NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA...
NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana...
NuCana Reports First Quarter 2024 Financial Results and Provides Business Update Key Data Readouts on Track for All Programs in 2024...
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement EDINBURGH, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- NuCana plc...
NuCana Announces Completion of ADS Ratio Change EDINBURGH, United Kingdom, April 16, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA...
NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy...
NuCana Announces Plan to Implement ADS Ratio Change EDINBURGH, United Kingdom, March 27, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA...
NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update Announced Encouraging Updates from NUC-3373...
NuCana to Present at TD Cowen’s 44th Annual Health Care Conference EDINBURGH, United Kingdom, Feb. 27, 2024 (GLOBE NEWSWIRE) -- NuCana plc...
NuCana to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference EDINBURGH, United Kingdom, Feb. 06, 2024 (GLOBE...
NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update Announced Encouraging Updates from NUC-3373 and NUC-7738...
NuCana Announces Listing Transfer to Nasdaq Capital Market EDINBURGH, United Kingdom, Nov. 10, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:...
NuCana to Present at the Jefferies London Healthcare Conference EDINBURGH, United Kingdom, Nov. 08, 2023 (GLOBE NEWSWIRE) -- NuCana plc...
NuCana to Participate in the Truist Securities 2023 BioPharma Symposium EDINBURGH, United Kingdom, Nov. 01, 2023 (GLOBE NEWSWIRE) -- NuCana...
NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.